Carrillo-Garcia, Jaime; Hindi, Nadia; Conceicao, Magda; Sala, Maria Angeles; Ugalde, Aitziber; Lopez-Pousa, Antonio; Bague, Silvia; Sevilla, Isabel; Vicioso, Luis; Ramos, Rafael; Martinez-Trufero, Javier; Mateo, Ma Carmen Gomez; Cruz, Josefina; Hernandez-Leon, Carmen Nieves; Redondo, Andres; Mendiola, Marta; Garcia, Jeronimo Martinez; Hernandez, Jose Emilio; Alvarez, Rosa; Agra, Carolina; de Juan-Ferre, Ana; Valverde, Claudia; Cano, Juana Maria; de Sande, Luis Miguel; Perez-Fidalgo, Jose A.; Lavernia, Javier; Marcilla, David; Gutierrez, Antonio; Moura, David S.; Martin-Broto, Javier

A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors

一项LY4170156（一种靶向叶酸受体α（FRα）表达型晚期实体瘤的抗体制剂偶联物）的首次人体I期研究

ANNALS OF ONCOLOGY

IF65.4

2024-09-011

PRE

A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (vol 24, 876, 2024)

BMC CANCER

IF3.4

2024-07-290

OAAI

Leary, Alexandra; Estevez-Garcia, Purificacion; Sabatier, Renaud; Ray-Coquard, Isabelle; Romeo, Margarita; Barretina-Ginesta, Pilar; Gil-Martin, Marta; Garralda, Elena; Bosch-Barrera, Joaquim; Moran, Teresa; Martin-Martorell, Paloma; Nadal, Ernest; Gascon, Pere; Rodon, Jordi; Lizcano, Jose M.; Munoz-Guardiola, Pau; Fierro-Duran, Gemma; Pedros-Gamez, Oriol; Perez-Montoyo, Hector; Yeste-Velasco, Marc; Cortal, Marc; Perez-Campos, Antonio; Alfon, Jose; Domenech, Carles; Perez-Fidalgo, Alejandro; Oaknin, Ana

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer

BMC CANCER

IF3.4

2024-07-223

OAAI

ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

ESGO-ESMO-ESP共识会议关于卵巢癌的建议: 病理学和分子生物学以及早期，晚期和复发性疾病

ANNALS OF ONCOLOGY

IF65.4

2024-03-0146

Ledermann, J. A.; Matias-Guiu, X.; Amant, F.; Concin, N.; Davidson, B.; Fotopoulou, C.; Gonzalez-Martin, A.; Gourley, C.; Leary, A.; Lorusso, D.; Banerjee, S.; Chiva, L.; Cibula, D.; Colombo, N.; Croce, S.; Eriksson, A. G.; Falandry, C.; Fischerova, D.; Harter, P.; Joly, F.; Lazaro, C.; Lok, C.; Mahner, S.; Marme, F.; Marth, C.; McCluggage, W. G.; Mcneish, I. A.; Morice, P.; Nicum, S.; Oaknin, A.; Perez-Fidalgo, J. A.; Pignata, S.; Ramirez, P. T.; Ray-Coquard, I.; Romero, I.; Scambia, G.; Sehouli, J.; Shapira-Frommer, R.; Sundar, S.; Tan, D. S. P.; Taskiran, C.; van Driel, W. J.; Vergote, I.; Planchamp, F.; Sessa, C.; Fagotti, A.

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer

在1b期研究中，结合PARP和MEK抑制，有或没有anti-PD-L1，对BRCA野生型，铂敏感，复发性卵巢癌患者的主要结果和特征

CANCER

IF5.1

2024-01-301

OAAI

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

LANCET

IF88.5

2024-01-0155

OAAI

Oaknin, Ana; Gladieff, Laurence; Martinez-Garcia, Jeronimo; Villacampa, Guillermo; Takekuma, Munetaka; De Giorgi, Ugo; Lindemann, Kristina; Woelber, Linn; Colombo, Nicoletta; Duska, Linda; Leary, Alexandra; Godoy-Ortiz, Ana; Nishio, Shin; Angelergues, Antoine; Rubio, Maria Jesus; Farinas-Madrid, Lorena; Yamaguchi, Satoshi; Lorusso, Domenica; Ray-Coquard, Isabelle; Manso, Luis; Joly, Florence; Alarcon, Jesus; Follana, Philippe; Romero, Ignacio; Lebreton, Coriolan; Perez-Fidalgo, J. Alejandro; Yunokawa, Mayu; Dahlstrand, Hanna; D'Hondt, Veronique; Randall, Leslie

Associations between the New DNA-Methylation-Based Telomere Length Estimator, the Mediterranean Diet and Genetics in a Spanish Population at High Cardiovascular Risk

新的基于DNA甲基化的端粒长度估算器，地中海饮食与西班牙高心血管风险人群的遗传学之间的关联

ANTIOXIDANTS

IF6.6

2023-11-152

OAAI

Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial

ANNALS OF ONCOLOGY

IF65.4

2023-10-012

PRE

In silico analysis of HER2 enriched subtype and a HER2 index based on transcriptomic data of breast cancer compared to gastric and uterine serous carcinomas